← Human Trials & Peer-Reviewed Studies
Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial)
Plain-language guide to PMID 18786480 (2008): randomized controlled trial of BNP (Nesiritide) in 1,742 patients.
Key Facts
- PMID
- 18786480
- Journal
- Journal of the American College of Cardiology
- Year
- 2008
- Study type
- Randomized Controlled Trial
- Authors
- Masson S et al. (8 authors)
- DOI
- 10.1016/j.jacc.2008.04.069
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial looks at BNP (Nesiritide).
This study sought to evaluate the association between changes over time of N-terminal pro-brain natriuretic peptide (NT-proBNP) expressed in different ways and outcome in patients with stable and chronic heart failure (HF).
Why It Was Studied
Although previous studies examined the prognostic value of repeated determinations of BNP in HF, there are only limited data on the clinical utility of serial measurements of the inactive peptide NT-proBNP in a large population of ambulatory patients with chronic HF with sufficient follow-up time.
Who Took Part
According to the abstract, 1,742 patients were involved.
PubMed indexes the participants as middle-aged adults and older adults, both men and women.
How the Study Was Run
In design terms this was a randomized and placebo-controlled study.
Random assignment meant chance, not the researchers, decided who got BNP (Nesiritide) and who got the comparison, which limits bias.
Some patients received a placebo instead of BNP (Nesiritide), giving a reference point.
What Was Measured
Although previous studies examined the prognostic value of repeated determinations of BNP in HF, there are only limited data on the clinical utility of serial measurements of the inactive peptide NT-proBNP in a large population of ambulatory patients with chronic HF with sufficient follow-up time.
The subject headings attached to it are Heart Failure, Natriuretic Peptide, Brain, Peptide Fragments, Prognosis and Proportional Hazards Models.
What This Means in Plain Language
The paper is a randomized and placebo-controlled study of BNP (Nesiritide) in 1,742 patients.
With several hundred people or more, it is a fairly large study for this kind of research.
Its findings take up roughly 3 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2008 (Journal of the American College of Cardiology), a journal based in United States.
More context: the BNP (Nesiritide) compound page, all human trials.
Our Notes on the Compound
BNP (Nesiritide): B-type natriuretic peptide, a 32-amino-acid heart hormone; nesiritide (Natrecor) is a recombinant form used in acute heart failure.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.